To investigate the safety and efficacy of an investigational drug called ABT-719 on patients who are scheduled for a high risk major surgery including non-cardio pulmonary bypass, cardiothoracic, abdominal or vascular surgery. These patients must have at least one additional risk factor which puts them at a high risk for AKI. This study will evaluate the effect of ABT-719 on the prevention of AKI in study participants.
Subjects who are undergoing high risk major surgery and have at least one additional risk factor which puts them at a high risk for Acute Kidney Injury (AKI).
Subjects must have a screening visit to determine if they are eligible for the study. A medical history will be taken and routine blood tests will be done. A pregnancy test will be administered to women of childbearing potential. If you are eligible you will be randomly assigned to a study group to receive a specific drug dosage or placebo prior to, during and after surgery. Tests and procedures will be performed at Day 0 (surgery) through Day 7, Day 30, Day 60 and Day 90.
Participation in the study lasts approximately 4 months and include up to 13 study visits to the research center. Up to 8 visits may occur while you are hospitalized.
You may contact Theresa Boley,RN,MSN,APN,CCRP at 217.545.5000.
Stephen Hazelrigg, MD